Cystadenocarcinoma, Serous
"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Descriptor ID |
D018284
|
MeSH Number(s) |
C04.557.470.200.025.480.240 C04.557.470.590.480.240
|
Concept/Terms |
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 10 | 1 | 11 |
2018 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report. J Obstet Gynaecol Res. 2019 Mar; 45(3):743-747.
-
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study. Ann Surg Oncol. 2018 Nov; 25(12):3701-3708.
-
Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers. Am J Obstet Gynecol. 2018 11; 219(5):463.e1-463.e12.
-
Evanescence of Endometrial Carcinomas in Hysterectomy Specimens: Observations on the "Vanishing Cancer" Phenomenon. Int J Surg Pathol. 2019 Feb; 27(1):43-47.
-
The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma. Histopathology. 2018 Mar; 72(4):619-625.
-
Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma. APMIS. 2018 Jan; 126(1):45-55.
-
Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations. Ann Surg Oncol. 2017 Oct; 24(11):3413-3421.
-
The Hunt Continues for Early Ovarian Cancer Clues. JAMA. 2017 Jul 04; 318(1):14-16.
-
Age is associated with prognosis in serous ovarian carcinoma. J Ovarian Res. 2017 Jun 12; 10(1):36.
-
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017 09; 217(3):334.e1-334.e9.